Posts tagged drug candidate
HCW assumes coverage of DURECT at buy

H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28.

Read More
BTIG starts CoLucid Pharma at buy

BTIG initiated coverage of CoLucid Pharmaceuticals (NASDAQ:CLCD) with a “buy” rating and $58 price target, calling the company’s Lasmiditan drug candidate a game changer in acute migraine. The stock closed at $36.16 on Dec 21.

Read More
Mackie starts Aurinia Pharma at speculative buy

Mackie Research launched coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a “speculative buy” recommendation and a 12-month target price of $8. The stock closed at $3.03 on Monday.

Aurinia is developing voclosporin as a first-line treatment for lupus nephritis (LN) and advancing the drug candidate into Phase 3 trials.

Read More
Galectin completes enrollment in Phase 2b trial ahead of schedule

Galectin Therapeutics (NASDAQ:GALT) has completed enrollment one month early in its NASH-CX Phase 2b trial with 162 subjects with nonalcoholic steatohepatitis (NASH).

The Phase 2b study is testing the company’s GR-MD-02 drug candidate and is being conducted with a primary endpoint of hepatic venous pressure gradient, which the FDA may view as an acceptable surrogate for outcomes for registration trials in this patient population. Top-line results are expected in December 2017.

Read More
Antibe melanoma study in mice published

A new study of Antibe Therapeutics’ (OTCQB:ATBPF; TSX-V:ATE) ATB-346 drug candidate has shown promising results in the chemoprevention and treatment of melanoma in mice.

The article was published online in the September issue of the peer-reviewed journal, Pharmacological Research. It can be viewed here

Read More
HCW starts OncoMed Pharma at buy

H.C. Wainwright has launched coverage of OncoMed Pharmaceuticals (NASDAQ:OMED) with a “buy” rating and $20 price target. The stock closed at $11.87 on Wednesday.

“We believe OncoMed is entering a year of dramatic changes with upcoming opt-in decisions for its lead drug candidates expected from its three partners: Celgene, Bayer and GlaxoSmithKline,” writes analyst Shaunak Deepak.

Read More
Wainwright starts Mirna Therapeutics at buy

H.C. Wainwright initiated coverage of Mirna Therapeutics (NASDAQ:MIRN) with a ‘buy” rating and $6 price target, saying the company’s promising microRNA technology “could be a gift to long-term investors.” The stock was quoted at $2.50 on Monday afternoon.

“We believe the current Mirna share price offers an attractive entry point for long-term investors, as the stock is trading well below the $73-million June cash position,” writes analyst Shaunak Deepak.

Read More
OPKO completes acquisition of Transition Therapeutics

OPKO Health (NASDAQ:OPK) has completed the acquisition of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) by way of a plan of arrangement.

Under the transaction, shareholders of Transition will receive about 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO for each common share of Transition.

Read More
Anavex presents safety data in AD

Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto.

Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks.

Read More
Roth ups Celator Pharma price target to $26

Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday

“This is an important next step for Vyxeos on the path to what we believe is likely approval,” writes analyst Joseph Pantginis.

Read More
Maxim starts ContraVir Pharma at buy

Maxim Group has initiated coverage of ContraVir Pharmaceuticals (NASDAQ:CTRV) with a “buy” rating and price target of $4, calling the company an emerging anti-viral leader with two clean shots on goal. The stock closed at 97 cents on Thursday.

“ContraVir has two programs: one in shingles (Phase 3) and one in hepatitis B (Phase 1/2), both of which can be value drivers for the company,” writes analyst Jason Kolbert.

Read More
HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday.

“Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively low clinical and regulatory risk,” writes analyst Andrew Fein.

Read More
Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701.

The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have undergone radical prostatectomy for organ-localized prostate cancer.

Read More
Can-Fite reports preclinical data in erectile dysfunction

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose treatment in a preclinical diabetic model.

Can-Fite plans to file an IND application with the FDA for CF602 in the fourth quarter this year and plans to initiate a Phase 1 trial following IND approval.

Read More
HCW assumes coverage of Galmed at buy

H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday.

Galmed is focused on the development of a sole drug candidate, aramchol, as a potentially disease-modifying treatment for nonalcoholic steatohepatitis (NASH).

Read More
Soricimed posts positive SOR-C13 data in solid tumors

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.

The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments.  SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.

Read More
Transition Therapeutics reports TT401 trial results

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes.

TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects into a 24-week study, consisting of a 12-week randomized blinded stage followed by a 12-week open-label stage.

Read More
Soricimed names Cory VP of BD, Reeves chairman

Closely-held Soricimed Biopharma has named Bob Cory as VP of business development and appointed Tom Reeves, a director, as chairman.

Dr. Cory has over 20 years of business and corporate development leadership experience in the biopharmaceutical industry. Most recently, he was VP of business development with Qu Biologics. Mr. Reeves currently is president and CEO of closely-held Interface Biologics.

Read More